Zacks Investment Research downgraded shares of EAGLE PHARMACT (EGRX) from N/A to NEUTRAL on February 26, 2015, with a target price of $35.90.
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
To get a free copy of the research report on EAGLE PHARMACT (EGRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment